Comparator: Diclofenac sodium — Competitive Intelligence Brief

Comparator: Diclofenac sodium (Comparator: Diclofenac sodium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Rheumatology, Inflammation.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2 Pain Management, Rheumatology, Inflammation Small molecule

Target snapshot

Comparator: Diclofenac sodium (Comparator: Diclofenac sodium) — Organon and Co. Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: Diclofenac sodium TARGET	Comparator: Diclofenac sodium	Organon and Co	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
NSAID (Aceclofenac)	NSAID (Aceclofenac)	Dong-A ST Co., Ltd.	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1, COX-2
Naproxen Sodium + Codeine Phosphate	Naproxen Sodium + Codeine Phosphate	ibrahim doğru	marketed	NSAID + opioid analgesic combination	COX-1, COX-2, mu-opioid receptor
Ibuprofen, Hydrocortisone	Ibuprofen, Hydrocortisone	X-pert Med GmbH	marketed	NSAID + corticosteroid combination	COX-1, COX-2, glucocorticoid receptor
Acular LS	Acular LS	University of Colorado, Denver	marketed	Topical NSAID	COX-1, COX-2
Dexketoprofen Trometamol + Paracetamol	Dexketoprofen Trometamol + Paracetamol	Yuzuncu Yil University	marketed	NSAID + analgesic combination	COX-1, COX-2 (dexketoprofen); central prostaglandin synthesis and pain pathways (paracetamol)
Standard Dose Ibuprofen	Standard Dose Ibuprofen	Ottawa Hospital Research Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class